Founded in 2001, we are the third-largest peptide-focused CRDMO globally, providing comprehensive services from peptide discovery to commercial manufacturing. With operations spanning over 50 countries, we specialize in peptide NCE discovery, development, and manufacturing, along with oligonucleotide-based solutions, including peptide-drug conjugates and radionuclide conjugates.